Kidney Risk Assessment Using IGFBP7 and TIMP-2 Biomarkers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for identifying and managing acute kidney injury (AKI) and chronic kidney disease (CKD) lack sensitivity and specificity, particularly in predicting the risk of AKI superimposed on CKD, and fail to provide effective pre- and post-surgical kidney function management.
Innovation Solution
Calculating a risk score based on the urinary concentrations of insulin-like growth factor-binding protein 7 (IGFBP7) and tissue inhibitor of metalloproteinase 2 (TIMP-2) to assess the risk of CKD and AKI, using a composite score that compares pre-procedure urine samples to determine the likelihood of kidney frailty or disease, guiding clinical management and preventive measures.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current methods for identifying and managing AKI and CKD are used, then existing clinical practices are maintained, but sensitivity and specificity for predicting AKI risk are insufficient
Solution Approach 1:
The patent changes the parameters used for kidney injury assessment from traditional markers (creatinine, BUN) to a composite biomarker panel including IGFBP7, TIMP-2, and other proteins. This parameter transformation enables more sensitive and specific detection of kidney frailty and AKI risk, directly resolving the contradiction between measurement precision and reliability of current methods.
Solution Approach 2:
The invention creates a composite risk assessment model by combining multiple biomarkers (IGFBP7, TIMP-2, and other proteins) into an integrated diagnostic approach. This composite methodology leverages the synergistic information from different biomarkers to achieve superior prediction accuracy compared to single-marker approaches, thereby improving both sensitivity and specificity simultaneously.
2Loss of time
If traditional kidney function assessment methods are used, then existing diagnostic protocols are maintained, but early identification of kidney frailty and AKI risk is delayed
Solution Approach 1:
The patent implements preliminary action by measuring biomarkers such as IGFBP7 and TIMP-2 before surgical procedures or in the early stages of kidney stress. This pre-assessment capability allows clinicians to identify kidney frailty and implement preventive measures before actual AKI occurs, thereby reducing the time to early identification without compromising measurement precision.
Solution Approach 2:
The invention introduces biomarkers as intermediary substances that mediate between kidney injury processes and detectable signals. These intermediary molecules (IGFBP7, TIMP-2) provide early warning signals of kidney stress before traditional function markers change, enabling timely intervention while maintaining high detection accuracy.
3Adaptability or versatility
If generic kidney management protocols are used, then standardized care is provided, but individualized pre- and post-surgical care based on kidney health status is not achieved
Solution Approach 1:
The patent segments kidney management into distinct risk categories based on biomarker profiles (e.g., high IGFBP7/TIMP-2 indicating kidney frailty). This segmentation allows clinicians to tailor pre- and post-surgical care protocols to individual patient risk levels, providing customized management while maintaining organizational structure through defined risk strata.
Solution Approach 2:
The invention introduces dynamic, risk-stratified management protocols that adapt to individual patient biomarker profiles. Rather than static generic protocols, the system dynamically adjusts care intensity and type based on measured kidney frailty markers, enabling personalized care while using standardized biomarker thresholds to manage protocol complexity.
Data Source
AI summary
The present invention provides methods and compositions for identifying patients at risk of kidney injury. A risk score, which is a composite of a urinary concentration of IGFBP7 (insulin-like growth factor-binding protein 7) and a urinary concentration of TIMP-2 (tissue inhibitor of metalloproteinase 2), is determined obtained from the patient, and is used to manage patient treatment.